- Home
- MANH vs ASND Comparison
MANH vs ASND Comparison
Compare MANH & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANH | ASND |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 15.0B |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MANH | ASND |
|---|---|---|
| Price | $258.91 | $258.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | $276.00 | ★ $304.82 |
| AVG Volume (30 Days) | ★ 846.6K | 592.2K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $131,300,000.00 | N/A |
| Revenue This Year | $8.91 | $89.94 |
| Revenue Next Year | $8.03 | $46.86 |
| P/E Ratio | $94.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $119.06 | $188.07 |
| 52 Week High | $263.47 | $282.15 |
Technical Indicators
Market Signals| Indicator | MANH | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 70.34 | 63.64 |
| Support Level | $125.04 | $216.52 |
| Resistance Level | $263.47 | $260.91 |
| Average True Range (ATR) | 8.50 | 5.70 |
| MACD | 0.44 | 1.34 |
| Stochastic Oscillator | 84.01 | 82.11 |
Price Performance
Historical ComparisonAbout MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers worldwide.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.